Article Information
History
- March 5, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Matthew S. Durstenfeld, MD MAS1,*,†,
- Michael J. Peluso, MD MHS MPhil DTM&H2,*,
- Feng Lin, MS3,
- Noah D. Peyser, PhD4,
- Carmen Isasi, MD PhD5,
- Thomas W. Carton, PhD MS6,
- Timothy J. Henrich, MD PhD7,
- Steven G. Deeks, MD2,
- Jeffrey E. Olgin, MD3,
- Mark J. Pletcher, MD MPH4,
- Alexis L. Beatty, MD MAS3,4,
- Gregory M. Marcus, MD MAS3 and
- Priscilla Y. Hsue, MD1
- 1Division of Cardiology at ZSFG and Department of Medicine, University of California, San Francisco (UCSF), USA
- 2Division of HIV, Infectious Disease, & Global Medicine, UCSF, USA
- 3Division of Cardiology, Department of Medicine, UCSF, USA
- 4Department of Epidemiology and Biostatistics, UCSF, USA
- 5Department of Epidemiology & Population Health, Albert Einstein College of Medicine
- 6Louisiana Public Health Institute
- 7Department of Experimental Medicine, UCSF, USA
- ↵†Corresponding author:
Matthew S. Durstenfeld, MD MAS, Division of Cardiology, UCSF at Zuckerberg San Francisco General Hospital, 1001 Potrero Avenue, 5G8, San Francisco, CA 94110, USA, Tel: +1 628 206 5562; Fax: +1 628 206 5447, e-mail: matthew.durstenfeld{at}ucsf.edu, twitter: @durstenfeld
Author Contributions: Drs. Durstenfeld, Peluso, Henrich, Deeks, and Hsue designed the study with input from the CCS Executive Steering Committee including Drs. Marcus, Beatty, Olgin, Pletcher, and Peyser. Ms. Lin and Dr. Durstenfeld conducted the analyses. Dr. Peyser oversaw data management. Drs. Durstenfeld and Peluso wrote the first draft of the manuscript. Dr. Isasi and Dr. Carton recruited participants and provided critical input on the manuscript. All authors provided critical input and approved of the manuscript.
Posted March 05, 2023.
Association of Nirmatrelvir/Ritonavir Treatment with Long COVID Symptoms in an Online Cohort of Non-Hospitalized Individuals Experiencing Breakthrough SARS-CoV-2 Infection in the Omicron Era
